/

Società

En

Non verificato

Enterome

Di cosa scriviamo

Annunci EconomiciBiotecnologiaEventiFarmaceuticaMedicina Salute Benessere

8 comunicati stampa

Guarda tutti i comunicati

01/12/2025

Biotecnologia

Medicina Salute Benessere

Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial

Fonte

Emittente

1.00

0

12/11/2025

Biotecnologia

Medicina Salute Benessere

Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meeting

Fonte

Emittente

1.00

0

15/10/2025

Biotecnologia

Medicina Salute Benessere

Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463

Fonte

Emittente

1.00

0

22/06/2025

Biotecnologia

Annunci Economici

Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML

Fonte

Emittente

1.00

0

11/06/2025

Biotecnologia

Annunci Economici

Finanza

Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma

Fonte

Emittente

1.00

0

02/06/2025

Biotecnologia

Medicina Salute Benessere

Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML

Fonte

Emittente

1.00

0

29/05/2025

Biotecnologia

Medicina Salute Benessere

Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025

Fonte

Emittente

1.00

0

13/11/2024

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Eventi

Web e Social Network

Enterome to Host Webinar on New Clinical Data From the Ongoing Phase 1/2 ‘SIDNEY’ Trial of Lead Programme, EO2463

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0